Evidence map›Paper›PMID 41323471›Full record

ReviewJournal of translational autoimmunity2025

Emerging cell-based and cell-free therapeutic strategies for vitiligo.

Nasser Gholijani, Effat Noori, Zeinab Zarei-Behjani, Delsuz Rezaee, Maryam Khodaei, Gholamhossien Darya, Kobra Mehdinejadiani, Zeinab Dehghan

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational autoimmunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nasser GholijaniAutoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Effat NooriDepartment of Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran.
Zeinab Zarei-BehjaniDepartment of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran.
Delsuz RezaeeDepartment of Genetic, School of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran.
Maryam KhodaeiDepartment of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gholamhossien DaryaDepartment of Comparative Biomedical Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Kobra MehdinejadianiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zeinab DehghanDepartment of Comparative Biomedical Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is a chronic, acquired skin disorder characterized by the loss of pigmentation due to the destruction or dysfunction of melanocytes. Conventional treatments such as corticosteroids and phototherapy often produce limited and unpredictable outcomes. In recent years, novel therapeutic strategies-including both cell-based and cell-free approaches such as melanocyte transplantation, mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), stem cell secretome, and exosomes-have emerged as promising alternatives. These therapies aim to restore pigmentation by replenishing melanocytes, modulating immune responses, and mitigating oxidative stress. This review explores the mechanisms of action, clinical efficacy, and translational challenges associated with each approach. While melanocyte transplantation demonstrates the highest repigmentation success in stable cases, stem cell- and exosome-based therapies offer significant potential for personalized and long-term treatment of vitiligo.

Indexed as

Cell therapyExosomesMelanocyte transplantationMesenchymal stem cellsVitiligo

Identifiers

PMID41323471
PMCPMC12664403

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.